Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name BRAF mutant
Gene Variant Detail

BRAF mutant (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03839342 Phase II Binimetinib + Encorafenib Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) Active, not recruiting CAN 0
NCT06299839 Phase I PAS-004 PAS-004 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT02974725 Phase I LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUS 4
NCT05759728 Phase Ib/II CNA3103 A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer Recruiting AUS 0
NCT03714958 Phase I Siremadlin + Trametinib Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD) Completed FRA 0
NCT05564377 Phase II Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Recruiting USA 1
NCT03784378 Phase I RXDX-105 Continued Access to RXDX-105 Completed USA 0
NCT02050321 Phase II Acitretin + Vemurafenib A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma Terminated USA 0
NCT05502237 Phase III AB154 + Cisplatin + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Nab-paclitaxel AB154 + Carboplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel + Zimberelimab AB154 + Carboplatin + Nab-paclitaxel + Zimberelimab AB154 + Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab AB154 + Cisplatin + Pemetrexed Disodium + Zimberelimab Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 13
NCT04925986 Phase II Pembrolizumab + Sitravatinib Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC Terminated USA 0
NCT04985604 Phase Ib/II Pimasertib + Tovorafenib Tovorafenib Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors Recruiting USA | FRA | ESP | CAN | BEL | AUS 1
NCT03867799 Phase II Nivolumab + Relatlimab iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer Active, not recruiting GBR 0
NCT04566393 Expanded access Ulixertinib Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies Available USA 0
NCT04591431 Phase II Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) Active, not recruiting ITA 0
NCT04270591 Phase Ib/II SCC244 Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer Recruiting USA 2
NCT05619172 Phase II Cetuximab + SOT101 A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer Active, not recruiting FRA | ESP | BEL 0
NCT04892017 Phase Ib/II DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Recruiting USA 0
NCT04488003 Phase II Ulixertinib Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Terminated USA 0
NCT06005974 Phase II TAK-733 A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation Recruiting USA 0
NCT04515394 Phase II Cetuximab + Tepotinib Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) Terminated USA | ITA | GBR | FRA | ESP | BEL 2
NCT05564403 Phase II Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Recruiting USA 0
NCT04145297 Phase I Hydroxychloroquine + Ulixertinib Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH) Completed USA 0
NCT05609370 Phase Ib/II Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab Bevacizumab + Fluorouracil + LBL-007 Bevacizumab + Fluorouracil Bevacizumab + Capecitabine + LBL-007 + Tislelizumab Bevacizumab + Capecitabine + LBL-007 A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Recruiting USA | AUS 2
NCT04409639 Phase II Cobimetinib Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO) Recruiting USA 0
NCT03037385 Phase Ib/II Pralsetinib Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL 5
NCT05201352 Phase Ib/II Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride + XB2001 Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1alpha True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (TASKIN) Recruiting FRA 0
NCT01138085 Phase I Trametinib + Uprosertib Safety, Pharmacokinetics (PK) of AKT and MEK Combination Completed USA 0
NCT02407509 Phase I RO5126766 Everolimus + RO5126766 Phase I Trial of VS-6766 Alone and in Combination With Everolimus (RAF/MEK) Recruiting GBR 0
NCT04370704 Phase Ib/II INCAGN02385 + INCAGN02390 + Retifanlimab INCAGN02385 + INCAGN02390 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies Active, not recruiting USA | AUS 0
NCT02610361 Phase I Lifirafenib Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors Completed NZL | AUS 0
NCT03992456 Phase II Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Active, not recruiting USA 0
NCT04129515 Phase Ib/II Pembrolizumab NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis Not yet recruiting USA 0
NCT06208748 Phase II PLX9486 + Sunitinib SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST Not yet recruiting USA 0
NCT03972046 Phase II Dabrafenib + Talimogene laherparepvec + Trametinib Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Withdrawn USA 0
NCT03181100 Phase II Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer Active, not recruiting USA 0
NCT03875820 Phase I Defactinib + RO5126766 Phase I Trial of Defactinib and VS-6766. (FRAME) Active, not recruiting GBR 0
NCT01231594 Phase I Dabrafenib Trametinib A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 1
NCT03391232 Phase I PolyPEPI1018 Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO) Completed USA | ITA 0
NCT04425239 Phase II Fluorouracil + Irinotecan + Leucovorin + Panitumumab Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE) Completed ITA 0
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT05554367 Phase II Binimetinib + Palbociclib Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial Recruiting USA 0
NCT04457284 Phase II Cisplatin + Nivolumab + Temozolomide Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer Active, not recruiting USA 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP 2
NCT04105270 Phase II Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial Recruiting USA 0
NCT02693535 Phase II Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) Recruiting USA 0
NCT05487235 Phase I Atezolizumab + GDC-1971 Atezolizumab + GDC-1971 + Omeprazole A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | NZL | ESP | CAN | AUS 4
NCT03175224 Phase Ib/II Vebreltinib APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 6
NCT05117242 Phase II GEN1046 + Pembrolizumab GEN1046 Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU 2
NCT05291156 Phase II Cetuximab Avelumab + Cetuximab CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy Recruiting ITA 0
NCT06326411 Phase I NST-628 A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628) Recruiting AUS 0
NCT05629702 Phase II Nabiximols + Temozolomide Temozolomide ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids (ARISTOCRAT) Recruiting GBR 0
NCT04620330 Phase II Defactinib + RO5126766 RO5126766 A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (RAMP202) Completed USA | ITA | FRA | ESP | DEU 0
NCT01877811 Phase Ib/II RXDX-105 CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 Completed USA 0
NCT05312398 Phase II Cetuximab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen Active, not recruiting ITA 0
NCT03162627 Phase I Olaparib + Selumetinib Selumetinib and Olaparib in Solid Tumors Active, not recruiting USA 0
NCT06067776 Phase I Cetuximab + Osimertinib + Tucatinib Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer Not yet recruiting USA 0
NCT02860780 Phase I Prexasertib + Ralimetinib A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer Completed USA | DEU 0
NCT04609566 Phase II Brentuximab vedotin + Pembrolizumab Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors Recruiting USA | CAN 0
NCT04524689 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium + SAR408701 Cisplatin + Pemetrexed Disodium + SAR408701 Carboplatin + Pembrolizumab + SAR408701 Pembrolizumab + SAR408701 Cisplatin + Pembrolizumab + SAR408701 Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) (CARMEN-LC05) Active, not recruiting USA | FRA | ESP 5
NCT06328738 Phase I ELVN-002 + Eribulin + Trastuzumab Capecitabine + ELVN-002 + Trastuzumab ELVN-002 + Paclitaxel + Trastuzumab Capecitabine + ELVN-002 + Oxaliplatin + Trastuzumab ELVN-002 + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab ELVN-002 + Trastuzumab ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer Recruiting USA 0
NCT04495621 Phase Ib/II Cetuximab + MEN1611 MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (C-PRECISE-01) Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU 1
NCT03555149 Phase Ib/II Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) Terminated USA | FRA | AUS 2
NCT00770263 Phase I Erlotinib + Temsirolimus Erlotinib and Temsirolimus for Solid Tumors Completed USA 0
NCT01719380 Phase Ib/II Cetuximab + Encorafenib Alpelisib + Cetuximab + Encorafenib Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Completed USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT01531361 Phase I Sorafenib + Vemurafenib Crizotinib + Vemurafenib Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations Completed USA 0
NCT03051035 Phase I KO-947 First-in-Human Study of KO-947 in Non-Hematological Malignancies Terminated USA | ESP 0
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Completed USA | FRA | AUS 1
NCT03213691 Phase II Selumetinib Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT04916236 Phase I LY3214996 + RMC-4630 Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) Recruiting NLD 0
NCT05379595 Phase Ib/II Amivantamab-vmjw Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1) Recruiting USA | ITA | ESP | DEU | CAN | BEL 5
NCT01306045 Phase II Erlotinib Lapatinib MK2206 Sunitinib Selumetinib Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Active, not recruiting USA 0
NCT03091257 Phase I Dabrafenib + Trametinib Dabrafenib Trametinib A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma Unknown status USA 0
NCT01781429 Phase Ib/II Ulixertinib Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Completed USA 0
NCT04921358 Phase III Docetaxel Sitravatinib + Tislelizumab Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Terminated AUS 1
NCT01885195 Phase II Binimetinib MEK162 for Patients With RAS/RAF/MEK Activated Tumors Completed USA 0
NCT05886920 Phase I D3S-002 Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations Recruiting USA | AUS 1
NCT01841463 Phase Ib/II Vemurafenib + Voruciclib Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation Suspended USA 0
NCT04511845 Phase I SPYK04 A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). Recruiting USA 1
NCT03559049 Phase Ib/II Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT05259319 Phase I Atezolizumab + Tiragolumab Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT) Recruiting FRA 0
NCT03415126 Phase I ERAS-007 A Study of ASN007 in Patients With Advanced Solid Tumors Completed USA 0
NCT05831995 Phase I ABM-168 Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. Recruiting USA 0
NCT03272464 Phase I Dabrafenib + Itacitinib + Trametinib INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. Terminated USA 0
NCT01723202 Phase II Dabrafenib + Trametinib Dabrafenib Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting USA 0
NCT03874026 Phase II Cetuximab + Fluorouracil + Irinotecan + Leucovorin Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (CIFRA) Recruiting ITA 0
NCT06116786 Phase I Cetrelimab + JNJ-86974680 A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer Recruiting USA | ESP | DEU 1
NCT02130466 Phase Ib/II Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) Completed 0
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT01449058 Phase Ib/II Alpelisib + Binimetinib A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | AUS 1
NCT03396497 Phase I LYC-55716 + Pembrolizumab Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer Unknown status USA 0
NCT02747537 Phase II Irinotecan + Sorafenib Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan Withdrawn 0
NCT04072198 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NIVACOR) Unknown status ITA 0
NCT04800822 Phase I PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 PF-07284892 in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT02296112 Phase II Trametinib Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations Completed USA 0
NCT02648490 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers Completed USA 1
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Completed USA 0
NCT04776655 Phase III Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb) Recruiting ITA 0
NCT04190628 Phase I ABM-1310 ABM-1310 + Cobimetinib Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT03218826 Phase I AZD8186 + Docetaxel PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03696212 Phase Ib/II Grapiprant + Pembrolizumab Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma Terminated USA 0
NCT02428712 Phase Ib/II PLX8394 A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors Active, not recruiting USA 0
NCT01744652 Phase I Crizotinib + Dasatinib Dasatinib and Crizotinib in Advanced Cancer Completed USA 0
NCT04189055 Phase II Cetuximab + Irinotecan Cetuximab Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL) Recruiting FRA 0
NCT03664024 Phase II Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782) Completed USA | ESP | CAN 2
NCT05221320 Phase II Hydroxychloroquine + Ulixertinib Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Recruiting USA 0
NCT05203172 FDA approved Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN 0